Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pemetrexed | TYMS/DHFR/GARFT | TYMS | 70.1583 | 100.0000 | 100.0000 | 0.5012 | 0.6411 | 0.8577 | 0.5144 | 0.6941 | 0.8649 | 0.0000 | 0.7943 | 1.8547 | 0.0614 | 0.1870 | 0.3357 | 0.9463 | 34.1832 | 100.0000 | |
Methotrexate | DHFR | Metabolism | 0.1850 | 100.0000 | 100.0000 | 0.3067 | 0.6372 | 0.9078 | 0.3672 | 0.5884 | 0.9117 | 0.0000 | 2.3582 | 4.5415 | 0.0328 | 0.2767 | 0.4502 | 0.0331 | 0.1737 | 100.0000 | |
Baicalein | Lipoxygenase | Metabolism | 41.6425 | 70.6950 | 100.0000 | -0.0508 | 0.2583 | 0.5386 | -0.5772 | 0.0203 | 0.4255 | 1.6411 | 2.5826 | 3.9209 | 0.0595 | 0.1090 | 0.1450 | 32.6213 | 62.3319 | 100.0000 | |
Disulfiram | Proteasome | Proteasome | 0.2148 | 13.4616 | 100.0000 | -0.6139 | 0.0054 | 0.4486 | -0.9836 | -0.0088 | 0.5061 | 0.2242 | 2.0208 | 4.9998 | 0.1469 | 0.2459 | 0.3654 | 0.1623 | 16.2617 | 100.0000 | |
(Z)-4-Hydroxytamoxifen | ESR1 | N/A | 38.2142 | 72.1652 | 100.0000 | -0.2149 | 0.3051 | 0.6418 | -0.8145 | -0.0997 | 0.5442 | 0.6236 | 1.8012 | 2.9451 | 0.0928 | 0.1395 | 0.2253 | 17.7725 | 43.7586 | 100.0000 | |
Ibandronate | FDPS | N/A | 49.3295 | 82.7741 | 100.0000 | -0.5209 | -0.1213 | 0.0387 | -0.7048 | -0.2169 | -0.0113 | 0.9599 | 1.4483 | 1.9155 | 0.2062 | 0.2750 | 0.3199 | 66.6332 | 98.6899 | 100.0000 | |
CGC-11047 | Polyamine analogue | N/A | 43.1451 | 85.4630 | 100.0000 | -0.8722 | -0.7234 | -0.2437 | -1.0000 | -0.9172 | -0.4365 | 0.4134 | 0.5735 | 1.1488 | 0.3172 | 0.3971 | 0.4905 | 94.6485 | 100.0000 | 100.0000 | |
Glycyl-H-1152 | ROCK2 | N/A | 7.8389 | 29.5632 | 100.0000 | 0.0725 | 0.4318 | 0.6407 | -0.4259 | 0.0666 | 0.6245 | 0.3449 | 0.9010 | 2.0476 | 0.0704 | 0.1476 | 0.1891 | 2.5420 | 16.8696 | 100.0000 | |
AG1478 | EGFR | ErbB | 8.7673 | 51.6075 | 100.0000 | -0.0710 | 0.2684 | 0.6341 | -0.3109 | -0.0273 | 0.4206 | 0.8939 | 1.7205 | 2.6373 | 0.0902 | 0.1531 | 0.2936 | 3.7212 | 36.6666 | 94.4655 | |
Nutlin 3a | MDM2 | MDM2 | 15.2348 | 24.3890 | 41.8634 | -0.3252 | -0.0482 | 0.2155 | -1.0000 | -0.8163 | -0.2697 | 1.1456 | 1.7429 | 2.5635 | 0.0828 | 0.1397 | 0.2099 | 23.6810 | 39.7952 | 62.9892 | |
L-779450 | BRAF | MAPK | 12.8318 | 28.9246 | 48.0158 | -0.2622 | 0.2749 | 0.3891 | -1.0000 | -0.6190 | -0.1023 | 1.0435 | 1.8204 | 3.7221 | 0.0544 | 0.0922 | 0.1394 | 20.7244 | 44.1580 | 61.2878 | |
NU6102 | CDK1/2 | CDK | 12.2242 | 17.3275 | 31.6450 | -0.7759 | -0.4783 | -0.1439 | -1.0000 | -0.9972 | -0.6085 | 1.3221 | 1.8051 | 3.6950 | 0.1178 | 0.1554 | 0.2440 | 20.2928 | 27.4520 | 55.8294 | |
Purvalanol A | CDK1 | CDK | 25.2896 | 54.7310 | 100.0000 | 0.0757 | 0.5333 | 0.7416 | -0.0675 | 0.5068 | 0.7450 | 1.0817 | 2.5000 | 4.2404 | 0.0335 | 0.0774 | 0.1767 | 18.1854 | 35.4887 | 52.3768 | |
TPCA-1 | IKK | NFKB | 4.9121 | 23.5816 | 100.0000 | 0.0988 | 0.4346 | 0.6277 | -0.1071 | 0.3912 | 0.5674 | 0.5796 | 1.2158 | 2.2892 | 0.0966 | 0.1616 | 0.2244 | 2.5700 | 5.7466 | 43.2238 | |
Temsirolimus | MTOR | MTOR | 0.1192 | 1.7003 | 10.0307 | -0.9332 | -0.8176 | -0.6679 | -1.0000 | -1.0000 | -0.9967 | 0.2520 | 0.4363 | 1.0813 | 0.3951 | 0.4933 | 0.6311 | 6.4751 | 18.8586 | 43.0334 | |
Oxaliplatin | DNA cross-linker | DNA cross-linker | 3.2681 | 4.9333 | 12.0662 | -0.9391 | -0.8084 | -0.7104 | -1.0000 | -1.0000 | -0.9516 | 0.6228 | 0.7486 | 1.0057 | 0.4005 | 0.5419 | 0.5768 | 14.7918 | 22.6957 | 42.6124 | |
Gefitinib | EGFR | ErbB | 6.6704 | 12.9191 | 28.3915 | -0.2671 | 0.0424 | 0.3018 | -0.8465 | -0.5620 | -0.2259 | 0.9170 | 1.3719 | 2.5436 | 0.0767 | 0.1382 | 0.2408 | 9.0805 | 26.2291 | 41.5832 | |
Cisplatin | DNA cross-linker | DNA cross-linker | 4.4823 | 11.6380 | 25.2438 | -0.8850 | -0.6449 | -0.2565 | -0.9047 | -0.5931 | -0.2921 | 1.0217 | 1.3698 | 2.2177 | 0.2715 | 0.3752 | 0.4391 | 8.7984 | 21.1543 | 38.4325 | |
Imatinib | ABL/KIT/PDGFR | nRTK | 18.5481 | 21.7914 | 25.5570 | -0.9852 | -0.9632 | -0.8948 | -0.9969 | -0.9814 | -0.8936 | 2.2328 | 2.7060 | 3.3541 | 0.3997 | 0.4467 | 0.4851 | 27.9144 | 31.9309 | 36.9254 | |
CPT-11 | TOP1 | TOP | 3.1544 | 10.7270 | 20.8553 | -0.5980 | -0.2192 | 0.1666 | -0.9688 | -0.6234 | -0.1292 | 0.8799 | 1.3528 | 1.8883 | 0.1220 | 0.2195 | 0.2928 | 7.3583 | 23.7091 | 36.8667 | |
Tozasertib | AURK/FLT3/ABL/JAK2 | AURK | 0.9523 | 4.3787 | 11.8540 | -0.5661 | -0.3376 | -0.0359 | -1.0000 | -1.0000 | -0.4350 | 0.4858 | 0.8218 | 1.3502 | 0.1794 | 0.3014 | 0.3656 | 4.7346 | 16.5294 | 34.8041 | |
Trametinib | MEK | MAPK | 0.1119 | 60.3200 | 100.0000 | 0.2676 | 0.5669 | 0.7582 | 0.2515 | 0.4183 | 0.5896 | 0.4854 | 1.1532 | 1.7735 | 0.0718 | 0.1864 | 0.3779 | 0.0100 | 0.4479 | 33.6419 | |
Trichostatin A | HDAC | HDAC | 6.5374 | 11.5225 | 17.5553 | -0.9202 | -0.8512 | -0.7541 | -0.9053 | -0.8178 | -0.6756 | 1.3647 | 1.8955 | 2.2777 | 0.6490 | 0.7724 | 0.9158 | 11.0302 | 20.2024 | 30.2620 | |
Everolimus | MTOR | MTOR | 0.0432 | 0.6717 | 4.3873 | -0.8294 | -0.6714 | -0.2303 | -1.0000 | -1.0000 | -0.6838 | 0.2890 | 0.4230 | 0.7677 | 0.3295 | 0.4415 | 0.5925 | 1.5205 | 9.7227 | 26.2255 | |
Nelfinavir | N/A | N/A | 8.4034 | 9.7440 | 15.4339 | -0.8211 | -0.6445 | -0.2989 | -1.0000 | -1.0000 | -0.8006 | 1.6805 | 2.3548 | 2.7767 | 0.1130 | 0.1589 | 0.1970 | 12.4011 | 15.3815 | 22.7642 |